Strategic Diagnostics Reports Fourth Quarter and Full-Year Financi...( Sixth Consecutive Quarter of Double-...)

Sixth Consecutive Quarter of Double-Digit Year-over-Year Revenue Increases from Antibody Technology (up 28%); Third Consecutive Quarter of More Than

20% Year-over-Year Growth in Food Pathogen Testing Business

NEWARK, Del., Feb. 28 /PRNewswire-FirstCall/ -- Strategic Diagnostics Inc. (Nasdaq: SDIX) - reported that total revenues for the quarter ended December 31, 2007, were $7.3 million, an increase of 4% over the fourth quarter of 2006. Revenues for the 2007 fourth quarter were positively impacted by a 28% increase in sales of antibody products and 21% growth in the sales of food pathogen testing methods, in both cases as compared to the fourth quarter of 2006. These increases were offset somewhat by the continuing decline in the Company's legacy U.S. Ag/GMO business of 65% as compared to the fourth quarter of 2006. Full-year total revenue increased 7% to $27.2 million versus $25.5 million for the same period in 2006.

Fourth Quarter and Recent Highlights

-- The Company's new, sequence-based, Genomic Antibody Technology(TM)

(GAT) platform continued to accelerate and earn market acceptance

within the life science industry as a proven tool for advancing

therapeutic and diagnostic product development efforts:

- Project bookings for "custom" GAT projects exceeded the

$1 million mark over the last seven months of 2007, following the

introduction of the full-range of GAT offerings during May 2007,

with more than half of these new projects booked during the

fourth quarter.

- The Company's new Internet-based catalog of proprietary,

SEQer(TM) brand antibody reagents was launched during th
'/>"/>